Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

Phase 2DabogratinibNeutral

AI Analysis

Summary

Tyra Biosciences announced a conference call scheduled for September 9, 2026 to discuss initial results from the SURF302 Phase 2 study evaluating oral dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.

Clinical Trial Data

Phase

Phase 2

Importance:6/10

Sentiment:

0.00

Phase 2 data readoutFGFR biologyoral drugconference call announcement

Related Companies

$TYRA

Read the original article

Published by PR Newswire Biotech on September 4, 2026 12:00 PM

Read Original